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BACKGROUND
Prior studies with the use of a prospective–retrospective design including archival tumor 
samples have shown that gene-expression assays provide clinically useful prognostic infor-
mation. However, a prospectively conducted study in a uniformly treated population provides 
the highest level of evidence supporting the clinical validity and usefulness of a biomarker.
METHODS
We performed a prospective trial involving women with hormone-receptor–positive, human 
epidermal growth factor receptor type 2 (HER2)–negative, axillary node–negative breast 
cancer with tumors of 1.1 to 5.0 cm in the greatest dimension (or 0.6 to 1.0 cm in the 
greatest dimension and intermediate or high tumor grade) who met established guide-
lines for the consideration of adjuvant chemotherapy on the basis of clinicopathologic 
features. A reverse-transcriptase–polymerase-chain-reaction assay of 21 genes was per-
formed on the paraffin-embedded tumor tissue, and the results were used to calculate a 
score indicating the risk of breast-cancer recurrence; patients were assigned to receive 
endocrine therapy without chemotherapy if they had a recurrence score of 0 to 10, indicat-
ing a very low risk of recurrence (on a scale of 0 to 100, with higher scores indicating a 
greater risk of recurrence).
RESULTS
Of the 10,253 eligible women enrolled, 1626 women (15.9%) who had a recurrence 
score of 0 to 10 were assigned to receive endocrine therapy alone without chemotherapy. 
At 5 years, in this patient population, the rate of invasive disease–free survival was 
93.8% (95% confidence interval [CI], 92.4 to 94.9), the rate of freedom from recurrence 
of breast cancer at a distant site was 99.3% (95% CI, 98.7 to 99.6), the rate of freedom 
from recurrence of breast cancer at a distant or local–regional site was 98.7% (95% CI, 
97.9 to 99.2), and the rate of overall survival was 98.0% (95% CI, 97.1 to 98.6).
CONCLUSIONS
Among patients with hormone-receptor–positive, HER2-negative, axillary node–negative 
breast cancer who met established guidelines for the recommendation of adjuvant chemo-
therapy on the basis of clinicopathologic features, those with tumors that had a favorable 
gene-expression profile had very low rates of recurrence at 5 years with endocrine thera-
py alone. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, 
NCT00310180.)
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Breast cancer is the most common cancer in women worldwide and in the United States, and it is the leading cause 
of death from cancer in women worldwide.1 Prog-
nostic factors for the recurrence of breast cancer 
at a distant site regardless of treatment include 
clinicopathologic features such as tumor size and 
grade and the number of axillary lymph nodes 
with metastasis.2 Predictive factors that identify 
a benefit from specific therapies include the ex-
pression of the estrogen receptor and the pro-
gesterone receptor, which identifies patients who 
benefit from adjuvant endocrine therapy,3 and 
overexpression of the human epidermal growth 
factor receptor 2 (HER2) protein (or HER2 gene 
amplification),4 which identifies patients who ben-
efit from adjuvant HER2-directed therapy. Adju-
vant chemotherapy reduces the risk of recurrence, 
even among patients with axillary node–negative 
disease who are at lower risk for recurrence.5-7
For contemporary taxane-based or anthracy-
cline-based chemotherapy regimens, proportional 
reductions in risk have been shown to be affected 
only minimally by age, nodal status, tumor grade, 
estrogen-receptor expression, or use of adjuvant 
endocrine therapy.8 These findings led a National 
Institutes of Health consensus panel in 2001 to 
conclude that “adjuvant polychemotherapy . . . 
should be recommended to the majority of 
women with localized breast cancer regardless 
of lymph node, menopausal, or hormone receptor 
status.”9 The widespread use of adjuvant chemo-
therapy has contributed to the declining breast-
cancer mortality that has been observed in the 
United States and other industrialized nations.10
More than 100,000 women in the United 
States received a diagnosis of estrogen-receptor–
positive breast cancer associated with negative 
axillary lymph nodes in 2014.11 Although ap-
proximately 85% of these women may be recur-
rence-free at 10 years with adjuvant endocrine 
therapy alone, the addition of chemotherapy 
leads to a relative reduction in the risk of recur-
rence of approximately 30% on average, which 
translates into an absolute benefit in the rate of 
freedom from recurrence of up to 5 percentage 
points.12,13 Many patients with estrogen-receptor–
positive breast cancer would therefore be over-
treated with chemotherapy on the basis of clini-
copathologic features alone, since most would 
have been adequately treated with endocrine 
therapy alone.14
Previous studies have shown that a 21-gene 
expression assay provides additional prognostic 
information independent of clinicopathologic 
features15 and also predicts benefit from adju-
vant chemotherapy in estrogen-receptor–positive 
disease.16,17 Prospective validation was performed 
with the use of archival tumor specimens from 
completed studies that used a prospective–retro-
spective design.18 However, validation in prospec-
tively conducted studies provides the highest 
level of evidence supporting the clinical validity 
and ultimately the clinical usefulness of a new 
biomarker.19,20
Here we report the results of a prospectively 
conducted clinical trial, the Trial Assigning In-
dividualized Options for Treatment (TAILORx). 
This trial was designed to further validate and 
refine the clinical usefulness of the 21-gene as-
say (Oncotype DX Recurrence Score, Genomic 
Health) in a specified low-risk cohort of women 
with hormone-receptor–positive, HER2-negative, 
axillary node–negative invasive breast cancer.
Me thods
Study Patients
The study included women 18 to 75 years of age 
with axillary node–negative invasive breast can-
cer that was estrogen-receptor–positive or pro-
gesterone-receptor–positive (or both) and that 
did not overexpress HER2. Patients had to meet 
National Comprehensive Cancer Network guide-
lines for the recommendation of adjuvant chemo-
therapy,21 including a primary tumor size of 1.1 to 
5.0 cm in the greatest dimension for a tumor of 
any grade or a size of 0.6 to 1.0 cm in the great-
est dimension for a tumor of intermediate or 
high histologic grade or nuclear grade (or both).
Other eligibility criteria included an Eastern 
Cooperative Oncology Group (ECOG) perfor-
mance-status score of 0 or 1 (on a scale from 
0 to 5, with higher numbers indicating greater 
disability; a score of 0 indicates no symptoms, 
and a score of 1 mild symptoms) and normal 
hematologic, bone marrow, hepatic, renal, pul-
monary, and cardiac function. Patients with 
HER2-overexpressing disease were excluded be-
cause most have a high risk of recurrence14 and 
because such patients benefit from adjuvant 
HER2-directed therapy plus chemotherapy.22
Study Protocol
This prospective clinical trial was sponsored by 
the National Cancer Institute (NCI), was coordi-
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nated by the ECOG and subsequently the ECOG–
ACRIN Cancer Research Group, and included 
other participating NCI-sponsored groups. Pa-
tients were required to provide written informed 
consent, including willingness to have treatment 
assigned or randomly assigned on the basis of the 
genetic-assay results indicating the risk of recur-
rence.
All the patients had an Oncotype DX Recur-
rence Score, a reverse-transcriptase–polymerase-
chain-reaction 21-gene assay performed on RNA 
extracted from formalin-fixed paraffin-embed-
ded tissue, performed in a central laboratory 
(Genomic Health).15 The recurrence scores range 
from 0 to 100, with higher scores indicating a 
greater risk of recurrence. Patients with a score 
of 0 to 10 were assigned to receive endocrine 
therapy alone, and those with a score of 26 or 
higher were assigned to receive chemotherapy plus 
endocrine therapy. Prior studies indicated that 
patients with a score of less than 11 had a favor-
able prognosis with endocrine therapy alone15 
and also that patients with a score of 26 to 30 or 
higher derived substantially greater benefit from 
adjuvant chemotherapy.16,17 Patients with a mid-
range score of 11 to 25 were randomly assigned 
to receive either chemotherapy plus endocrine 
therapy or endocrine therapy alone because the 
benefits of chemotherapy were uncertain in this 
group, yet the risk of recurrence was high enough 
to suggest that chemotherapy might be beneficial.
To minimize the potential for undertreatment 
of the participants enrolled in our trial, the recur-
rence-score ranges used in our study differed 
from those that were originally defined as low 
(≤10 in our study vs. <18 in the original defini-
tion), intermediate (11 to 25 vs. 18 to 30), and 
high (≥26 vs. ≥31).14 The recurrence-score strata 
derived for the trial were based on prior studies 
that indicated that the risk of recurrence of breast 
cancer at a distant site at 10 years after diagnosis 
and a 5-year course of tamoxifen could be as 
high as 10% among patients with a score of 11 
(point estimate, 7%; 95% confidence interval [CI], 
5 to 10) and up to 20% among those with a score 
of 25 (point estimate, 16%; 95% CI, 13 to 20),15 
indicating a risk that was substantial enough for 
a recommendation of adjuvant chemotherapy in 
patients with a score of 11 or higher.14
Study Oversight
The manuscript was written by the first author; 
the final version of the manuscript incorporated 
some changes recommended by the coauthors 
and Genomic Health. Data were collected by the 
Cancer Trials Support Unit and the ECOG–
ACRIN Cancer Research Group Coordinating 
Center. All the authors vouch for the accuracy 
and completeness of the data and analyses pre-
sented and for the adherence of the study to the 
protocol, which is available with the full text of 
this article at NEJM.org. No commercial support 
was involved in the planning or execution of the 
study, although the genomic test used is com-
mercially available.
Study End Points
The standardized definitions for efficacy end 
points (STEEP) criteria were used for the end-
point definitions.23 The primary trial end point 
was a time-to-event analysis of the rate of sur-
vival free from invasive cancer, with an invasive-
cancer event defined as the first event of recur-
rence of ipsilateral breast tumor, local recurrence, 
regional recurrence, distant recurrence, contra-
lateral second primary invasive cancer, second 
primary nonbreast invasive cancer (excluding 
nonmelanoma skin cancer), or death without 
evidence of recurrence (which corresponds to 
the STEEP definition of invasive disease–free 
survival).
Secondary end points included time-to-event 
analyses of the freedom from the recurrence of 
breast cancer at a distant site, with an event of 
breast cancer at a distant site defined as the first 
event of distant recurrence of breast cancer or 
death with distant recurrence, if death was the 
first manifestation of distant recurrence (which 
corresponds to the STEEP definition of distant 
recurrence–free interval); freedom from any re-
currence, with recurrence defined as the first 
recurrence of breast cancer at any site (including 
ipsilateral breast cancer, local or regional recur-
rence, or distant recurrence) or death with recur-
rence, if death was the first manifestation of 
recurrence (which corresponds to the STEEP 
definition of recurrence-free interval); and the 
overall survival rate, which was defined as the 
proportion of patients who did not die (from any 
cause). End-point assessments that were consis-
tent with standard of care at regular intervals 
were specified in the protocol, and copies of 
source documents supporting each event were 
reviewed and corroborated by one of the coau-
thors who did not have knowledge of the study 
group or the recurrence-score information.
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Statistical Analysis
The overall sample size in all the risk strata de-
fined according to recurrence score was driven 
by the need to include a sufficient number of 
patients with a score of 11 to 25 (midrange risk) 
in order to test the noninferiority of endocrine 
therapy alone versus chemotherapy plus endo-
crine therapy. At the fourth planned interim 
analysis held on March 20, 2015, the ECOG–
ACRIN data and safety monitoring committee 
recommended that the results of the low-risk 
group be released and that follow-up in the ran-
domized midrange-risk stratum and the nonran-
domized high-risk stratum continue as planned. 
Although there was no specific enrollment goal 
for the low-risk group, the large sample provided 
the opportunity to estimate 5-year event rates 
accurately.
Statistical comparisons of baseline character-
istics were calculated with the use of the chi-
square test for categorical variables and the 
Wilcoxon test and Student’s t-test for continuous 
variables. Tumor size in the greatest dimension, 
histologic grade of the tumor, and expression of 
estrogen receptor, progesterone receptor, and 
HER2 were determined locally and reported by 
the participating site.
Event-free rates were estimated with the use 
of the Kaplan–Meier method, with confidence 
intervals computed with the use of the log–log 
transformation and Greenwood’s variance. The 
data-cutoff date for the results presented here 
was July 29, 2015.
R esult s
Characteristics of the Patients
Between April 7, 2006, and October 6, 2010, we 
enrolled 10,273 patients in the trial, of whom 
10,253 were eligible to participate. A total of 
1629 patients (1626 of whom were eligible 
[15.9% of the total eligible population]) had a 
recurrence score of 0 to 10 (indicating low risk), 
6907 (6897 of whom were eligible [67.3% of the 
total eligible population]) had a score of 11 to 25 
(indicating midrange risk), and 1736 (1730 of 
whom were eligible [16.9% of the total eligible 
population]) had a score of 26 or higher (indicat-
ing high risk). The median follow-up in the low-
risk cohort was 69 months.
Table 1 shows the characteristics of the study 
population that was included in this analysis — 
patients with tumors associated with a recur-
rence score of 0 to 10 (low-risk cohort) — as 
compared with the characteristics of the patients 
who had a score of 11 to 25 (midrange-risk co-
hort). There were no significant differences in 
tumor size between these two cohorts. There 
was a similar distribution of intermediate-grade 
tumors (59% in the low-risk cohort and 57% in 
the midrange-risk cohort), although there was a 
significant difference in the distribution of grade, 
including low-grade tumors (34% vs. 29%) and 
high-grade tumors (7% vs. 14%) (P<0.001 for 
both comparisons). There were also significant 
but numerically modest differences between the 
low-risk cohort and the midrange-risk cohort with 
regard to age (median, 58 years vs. 55 years), 
menopausal status (postmenopausal status, 70% 
vs. 64%), progesterone-receptor expression (pro-
gesterone-receptor–positive, 98% vs. 92%), and 
type of primary surgery (lumpectomy, 68% vs. 
72%) (P<0.001 for all comparisons by the chi-
square test).
Adjuvant Therapy
In the low-risk cohort of 1626 patients, endo-
crine therapy included an aromatase inhibitor in 
963 patients (59%), tamoxifen in 560 (34%), se-
quential tamoxifen followed by aromatase-inhib-
itor therapy in 13 (1%), ovarian-function suppres-
sion in 44 (3%), or other or unknown therapy in 
46 (3%). Although the protocol specified that no 
chemotherapy be given if the recurrence score 
was 0 to 10, a total of 6 patients received adju-
vant chemotherapy (1 of whom had a recurrence 
despite adjuvant chemotherapy).
Event Rates at 5 Years
In the cohort of patients with a recurrence score 
of 0 to 10, there were 88 events of either invasive 
cancer or death and 30 deaths reported within 
5 years after study entry. The first event in the 
analysis of survival free from invasive disease 
was local or regional recurrence (or both) in 8 pa-
tients, distant recurrence in 10, invasive cancer 
of the opposite breast in 15, other invasive new 
primary cancer in 43, and death without another 
event in 12. The Kaplan–Meier estimates for 
each end point examined are shown in Figure 1.
In this cohort, the rate of invasive disease–
free survival at 5 years was 93.8% (95% CI, 92.4 
to 94.9). The rate of freedom from recurrence of 
breast cancer at a distant site at 5 years was 
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Characteristic
Recurrence Score, 
0–10 
(N = 1626)
Recurrence Score, 
11–25 
(N = 6897) P Value
Percent of all enrolled patients 15.9 67.3 —
Age
Median (interquartile range) — yr 58 (50–64) 55 (48–62) <0.001
Mean — yr 57±9 55±9 <0.001
Distribution — no. (%) <0.001
≤40 yr 58 (4) 319 (5)
41–50 yr 372 (23) 1964 (28)
51–60 yr 566 (35) 2503 (36)
61–70 yr 519 (32) 1811 (26)
>70 yr 111 (7) 300 (4)
Menopausal status — no./total no. (%) <0.001
Postmenopausal 1143/1623 (70) 4396/6873 (64)
Premenopausal 480/1623 (30) 2477/6873 (36)
Tumor size in the greatest dimension
Median (interquartile range) — cm 1.5 (1.2–2.0) 1.5 (1.2–2.0) 0.31
Mean — cm 1.74±0.77 1.71±0.79 0.23
Distribution — no./total no. (%) 0.42
<1.0 cm 128/1626 (8) 568/6883 (8)
1.0–1.9 cm 993/1626 (61) 4270/6883 (62)
2.0–2.9 cm 366/1626 (23) 1543/6883 (22)
3.0–3.9 cm 104/1626 (6) 358/6883 (5)
≥4.0 cm 35/1626 (2) 144/6883 (2)
Histologic grade of tumor — no./total no. (%) <0.001
Low 530/1578 (34) 1941/6665 (29)
Intermediate 937/1578 (59) 3812/6665 (57)
High 111/1578 (7) 912/6665 (14)
Estrogen-receptor expression — no./total no. (%) 0.28
Negative 5/1626 (<1) 10/6885 (<1)
Positive 1621/1626 (>99) 6875/6885 (>99)
Progesterone-receptor expression — no./total no. (%) <0.001
Negative 28/1590 (2) 528/6752 (8)
Positive 1562/1590 (98) 6224/6752 (92)
Primary surgery — no./total no. (%) <0.001
Lumpectomy 1106/1626 (68) 4986/6885 (72)
Mastectomy 520/1626 (32) 1899/6885 (28)
*  Plus–minus values are means ±SD. Patients were assigned to a risk cohort on the basis of the recurrence score on the 
21-gene assay. Scores range from 0 to 100, with higher scores indicating a greater risk of recurrence. Patients with a 
score of 0 to 10 were included in the low-risk cohort and were assigned to receive endocrine therapy alone. Patients 
with a score of 11 to 25 were included in the midrange-risk cohort and were randomly assigned to receive either che-
motherapy plus endocrine therapy or endocrine therapy alone. (Patients with a score of ≥26 were assigned to receive 
chemotherapy plus endocrine therapy and were not included in this analysis.) Statistical comparisons were calculated 
with the use of the chi-square test for categorical variables and the Wilcoxon test and Student’s t-test for continuous 
variables. Tumor size in the greatest dimension, histologic grade of the tumor, and expression of estrogen receptor, 
progesterone receptor, and HER2 were determined locally and reported by the participating site. Percentages may not 
total 100 because of rounding.
Table 1. Characteristics of the Patients at Baseline, According to Recurrence-Score Cohort.*
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99.3% (95% CI, 98.7 to 99.6), the rate of freedom 
from recurrence at 5 years was 98.7% (95% CI, 
97.9 to 99.2), and the rate of overall survival at 
5 years was 98.0% (95% CI, 97.1 to 98.6).
Multivariate Analysis and Effect of Tumor 
Grade and Age of the Patient
In a multivariate analysis that included age (≤50 
years vs. 51 to 60 years vs. 61 to 75 years), tumor 
size (2.1 to 5.0 cm vs. ≤2 cm in the greatest 
dimension), histologic grade (high vs. interme-
diate vs. low), and surgery type (mastectomy vs. 
lumpectomy), only histologic grade showed a 
significant association with the rate of freedom 
from recurrence. However, histologic grade did 
not show a significant association with the rate 
of invasive disease–free survival or the rate of 
freedom from distant recurrence (Table 2). Re-
currence rates were very low regardless of histo-
logic grade (Table 3).
Figure 1. Kaplan–Meier Estimates in the Analyses of Invasive Disease–free Survival, Freedom from Recurrence of Breast Cancer at a Distant 
Site, Freedom from Recurrence at Any Site, and Overall Survival.
A total of 1626 patients with a recurrence score of 0 to 10 (on a scale from 0 to 100, with higher scores indicating a greater risk of recurrence) 
were included in the analyses. In the time-to-event analysis of invasive disease–free survival, Panel A shows the probability of freedom 
from the first event of recurrence of ipsilateral breast tumor, local recurrence, regional recurrence, distant recurrence, contralateral second 
primary invasive cancer, second primary nonbreast invasive cancer (excluding nonmelanoma skin cancer), or death without evidence of 
recurrence (which corresponds to the standardized definitions for efficacy end points [STEEP]23 definition of invasive disease–free survival). 
In the time-to-event analysis of freedom from the recurrence of breast cancer at a distant site, Panel B shows the probability of freedom 
from the first event of distant recurrence of breast cancer or death with distant recurrence, if death was the first manifestation of distant re-
currence (which corresponds to the STEEP definition of distant recurrence–free interval). In the time-to-event analysis of freedom from re-
currence at any site, Panel C shows the probability of freedom from the first event of recurrence of breast cancer (ipsilateral breast cancer, 
local or regional recurrence, or distant recurrence) or the date of death with recurrence, if death was the first manifestation of recurrence 
(which corresponds to the STEEP definition of recurrence-free interval). Panel D shows the probability of overall survival in the time-to-
event analysis. In each panel, dashed lines indicate 95% confidence intervals and the insets show the same data on an enlarged y axis.
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Discussion
We performed a prospective validation study of a 
21-gene assay in patients with hormone-receptor–
positive, HER2-negative breast cancer who had a 
low risk of recurrence according to clinicopatho-
logic features but who nevertheless met estab-
lished clinical guidelines for the recommenda-
tion or consideration of adjuvant chemotherapy. 
In patients who were found to have a low risk of 
recurrence on the basis of genetic-assay results 
and who were thus assigned to receive endocrine 
therapy alone, the risk of the recurrence of breast 
cancer at a distant site was less than 1% and the 
risk of any recurrence was less than 2% at 5 years.
Recurrence events were uncommon regardless 
of histologic grade and were not significantly 
affected by younger age at diagnosis. In fact, in 
this low-risk population, the rate of recurrence 
events at 5 years was far exceeded by the rates of 
second primary breast cancers, other second 
primary-cancer events, and deaths from other 
causes, which resulted in a rate of invasive dis-
ease–free survival that was nearly 5 percentage 
points lower than the rate of freedom from re-
currence (93.8% vs. 98.7%).
Although adjuvant chemotherapy reduced the 
risk of distant recurrence and local–regional re-
currence in the Early Breast Cancer Trialists 
meta-analysis, there was only a marginal effect 
in reducing the risk of contralateral breast can-
cer and no effect on the risk of second primary 
cancers or on nonbreast-cancer mortality after 
15 years of follow-up in nearly 29,000 patients 
who had been randomly assigned to receive either 
chemotherapy or no chemotherapy.12 The low rate 
of distant recurrence observed in this prospec-
tive study is consistent with the rate observed at 
5 years in the original prospective–retrospective 
validation study involving patients with a low 
recurrence score of less than 18 (2.1%; 95% CI, 
0.6 to 3.7).14,15
The current prospectively conducted study sup-
ports the use of the 21-gene assay to spare the use 
of chemotherapy in patients who otherwise would 
be recommended to receive it on the basis of 
clinicopathologic features. These findings provide 
additional evidence supporting expert-derived 
clinical practice guidelines that recommend the 
use of this assay in patients with hormone- 
receptor–positive, axillary node–negative invasive 
breast cancer.21,24 Although this study clearly 
identifies patients who do not benefit from ad-
juvant chemotherapy, only 16% of the enrolled 
patients had a recurrence score of 10 or less. 
Approximately 67% of the patients enrolled in 
the trial had a midrange score of 11 to 25 and 
were randomly assigned to receive chemotherapy 
plus endocrine therapy or endocrine therapy 
alone. Continued follow-up is required in order 
to determine the effect of chemotherapy in this 
larger group of patients.
Late recurrence that occurs after 5 years ac-
counts for approximately one half of all distant 
recurrences in patients with estrogen-receptor–
End Point Hazard Ratio (95% CI) P Value
Recurrence, second primary breast cancer, 
second primary nonbreast 
invasive cancer, or death without 
recurrence of cancer
Tumor grade 0.13
Intermediate vs. low 1.56 (0.92–2.63)
High vs. low 2.05 (0.92–4.55)
Tumor size >2 cm vs. ≤2 cm 1.17 (0.71–1.92) 0.54
Age 0.07
51–60 yr vs. ≤50 yr 0.87 (0.46–1.64)
61–75 yr vs. ≤50 yr 1.53 (0.87–2.70)
Lumpectomy vs. mastectomy 0.63 (0.38–1.06) 0.07
Recurrence at a distant site
Tumor grade of high or intermediate 
vs. low†
3.83 (0.48–30.69) 0.14
Tumor size >2 cm vs. ≤2 cm 1.55 (0.38–6.31) 0.55
Age 0.27
51–60 yr vs. ≤50 yr 1.28 (0.12–4.22)
61–75 yr vs. ≤50 yr 3.49 (0.42–29.16)
Lumpectomy vs. mastectomy 0.57 (0.12–2.82) 0.47
Recurrence at any site
Tumor grade 0.02
Intermediate vs. low 8.07 (1.06–61.45)
High vs. low 4.73 (0.29–76.42)
Tumor size >2 vs. ≤2 cm 1.06 (0.33–3.33) 0.93
Age 0.33
51–60 yr vs. ≤50 yr 0.41 (0.10–1.73)
61–75 yr vs. ≤50 yr 0.98 (0.32–3.02)
Lumpectomy vs. mastectomy 0.93 (0.32–2.71) 0.89
*  Data from 1578 of 1626 patients with a recurrence score of 0 to 10 were in-
cluded in these analyses. Data from 48 patients for whom the histologic grade 
of the tumor was not reported were excluded from these analyses.
†  Data from patients with a high tumor grade and those with an intermediate 
tumor grade were combined for the analysis of freedom from the recurrence 
of breast cancer at a distant site because of the small number of events.
Table 2. Multivariate Analysis.*
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positive, HER2-negative breast cancer.25 There 
are several prognostic gene-expression assays 
for breast cancer,26 some of which are more ac-
curately prognostic for late recurrence than oth-
ers.27,28 However, the 21-gene assay predicts 
benefit from adjuvant chemotherapy,16,17 and 
chemotherapy prevents primarily early recur-
rences within 5 years after diagnosis.8 Therefore, 
although more recurrences are expected with 
longer follow-up, it is unclear whether these re-
currences would have been prevented by the 
early administration of adjuvant chemotherapy. 
Extended adjuvant endocrine therapy beyond 5 
years is effective in preventing late recurrence 
and may be considered when the treating clini-
cian and the patient perceive a favorable benefit–
risk ratio.29,30
The distribution of recurrence scores ob-
served in this prospective trial differs from the 
distribution that was initially projected on the 
basis of observations in a prior prospective–ret-
rospective validation study, which included 27% 
of patients with a score of 0 to 10, 43% with a 
score of 11 to 25, and 30% with a score of 26 or 
higher.14,16 This finding may be due to clinicians 
selecting patients for this study in whom there 
was therapeutic equipoise regarding the benefit 
of chemotherapy, which is reflected by the large 
proportion of patients who had tumors of 1.1 to 
2.0 cm in the greatest dimension or tumors of 
intermediate histologic grade. However, the dis-
tribution of scores that was observed in this 
trial is similar to the distribution observed by 
the commercial laboratory during the same time 
period in which the study was conducted (score 
of 0 to 10 in 18% of patients, score of 11 to 25 
in 62%, and score of ≥26 in 20%; Shak S, Ge-
nomic Health: personal communication). This 
finding indicates that the distribution of risk 
groups in the trial reflects clinical practice in 
the community and supports the generalizability 
of the study findings.
The RASTER (Microarray Prognostics in 
Breast Cancer) study was a prospective validation 
study that evaluated a different multigene assay, 
the 70-gene signature, in 427 patients with axil-
lary node–negative breast cancer.31 The 5-year 
rate of freedom from distant recurrence was 
97.0% among patients with a low-risk signature 
on the 70-gene assay (51% of all patients) and 
91.7% among those with a high-risk signature 
(49% of all patients).32 Decisions regarding adju-
vant systemic treatment were based on the 
Dutch Institute for Healthcare Improvement 
2004 guidelines, the 70-gene signature, and doc-
tors’ and patients’ preferences. Adjuvant chemo-
therapy was given to 169 patients (81%) with a 
high-risk signature and in 33 (15%) with a low-
risk signature. The outcomes observed in the 
RASTER study may therefore have been attribut-
able, at least in part, to chemotherapy adminis-
tered in selected patients in the low-risk group.
Tumor Grade
Invasive Disease–free 
Survival 
(95% CI)
Freedom from 
Distant Recurrence 
(95% CI)
Freedom from 
Any Recurrence 
(95% CI)
Overall Survival 
(95% CI)
All grades 93.8 (92.4–94.9) 99.3 (98.7–99.6) 98.7 (97.9–99.2) 98.0 (97.1–98.6)
Low grade 95.8 (93.5–97.3) 99.8 (98.3–100) 99.8 (98.3–100) 98.7 (97.0–99.4)
Intermediate grade 93.6 (91.7–95.1) 99.0 (98.0–99.5) 98.2 (97.0–99.0) 97.9 (96.8–98.7)
High grade 91.3 (83.9–95.4) 100 (NC–NC) 98.7 (91.1–99.8) 97.3 (91.9–99.1)
*  The analyses for all tumor grades included data from all 1626 patients who had a recurrence score of 0 to 10, including 
the 48 patients with the tumor grade not reported. A total of 530 patients were included in the analyses for low-grade 
tumor, 937 in the analyses for intermediate-grade tumor, and 111 in the analyses for high-grade tumor. In the time-to-
event analysis of invasive disease–free survival (primary end point), the rate indicates freedom from the first event of 
recurrence of ipsilateral breast tumor, local recurrence, regional recurrence, distant recurrence, contralateral second pri-
mary invasive cancer, second primary nonbreast invasive cancer (excluding nonmelanoma skin cancer), or death with-
out evidence of recurrence (which corresponds to the standardized definitions for efficacy end points [STEEP]23 defini-
tion of invasive disease–free survival). In the time-to-event analysis of recurrence of breast cancer at a distant site, the 
rate indicates freedom from the first event of distant recurrence of breast cancer or death with distant recurrence, if 
death was the first manifestation of distant recurrence (which corresponds to the STEEP distant recurrence–free inter-
val definition). In the time-to-event analysis of freedom from any recurrence, the rate indicates freedom from the first 
recurrence of breast cancer (ipsilateral breast cancer, local or regional recurrence, or distant recurrence) or the date of 
death with recurrence, if death was the first manifestation of recurrence (which corresponds to the STEEP recurrence-
free interval definition). NC denotes not calculated.
Table 3. Event Rates at 5 Years, According to Histologic Grade.*
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The MINDACT (Microarray in Node Negative 
Disease May Avoid Chemotherapy) trial is a pro-
spective trial in which patients were randomly 
assigned to receive chemotherapy or no chemo-
therapy on the basis of clinical criteria or the 
70-gene signature; enrollment has been com-
pleted and follow-up is ongoing.33 Although the 
results of the MINDACT trial are likely to pro-
vide important information, gene-expression as-
says bring added value by providing complemen-
tary predictive information that is independent 
of and does not correlate with clinicopathologic 
features in selected patients for whom this in-
formation may be clinically useful.34,35 Other 
ongoing trials (RxPONDER36 and OPTIMA37) are 
evaluating whether adjuvant chemotherapy is 
beneficial in patients with hormone-receptor–
positive, HER2-negative breast cancer with posi-
tive axillary lymph nodes and a recurrence score 
of 25 or less.
In conclusion, this prospective study involving 
uniformly treated patients with hormone-recep-
tor–positive, HER2-negative, axillary node–nega-
tive breast cancer supports the clinical validity 
of the 21-gene assay in identifying patients who 
may be safely spared adjuvant chemotherapy.
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